Overview

A Study of the Zanubrutinib Given in Combination With Bendamustine and Rituximab in (Elderly or TP53 Alterations or Chemotherapy Intolerance) Patients With Newly Diagnosed Mantle Cell Lymphoma

Status:
Recruiting

Trial end date:
2027-11-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the efficacy and safety of Zanubrutinib given in combination with bendamustine and rituximab in (elderly or TP53 alterations or chemotherapy intolerance) patients with newly diagnosed mantle cell lymphoma.

Phase:

Phase 2

Details

Lead Sponsor:

Ruijin Hospital

Treatments:

Bendamustine Hydrochloride
Rituximab
Zanubrutinib